July 8, 2021Open Access

Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment

Key Points

Key points are not available for this paper at this time.

Abstract

Hepatic impairment trial: ClinicalTrials.gov, NCT01790607 (https://clinicaltrials.gov/ct2/show/NCT01790607). Renal impairment trial: EudraCT Number: 2014-004575-23.

Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment

Key Points

Abstract

Cite This Study